Lv61
2490 积分 2022-02-25 加入
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
9小时前
待确认
Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?
6个月前
已完结
Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
6个月前
已完结
Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?
6个月前
已完结
Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104
7个月前
已完结
Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib
7个月前
已完结
Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database”
7个月前
已完结
Author’s Response to: Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database” and “Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness”
7个月前
已关闭
New promises and challenges in the treatment of advanced non-small-cell lung cancer
8个月前
已完结
皖公网安备34019202002308
